PaxMedica (PXMD) Competitors

PaxMedica has lower revenue, but higher earnings than Syros Pharmaceuticals. PaxMedica is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Syros Pharmaceuticals has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500. Comparatively, PaxMedica has a beta of -0.99, meaning that its share price is 199% less volatile than the S&P 500.

91.5% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 4.9% of PaxMedica shares are owned by institutional investors. 12.3% of Syros Pharmaceuticals shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Syros Pharmaceuticals' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

PaxMedica's return on equity of -3,167.89% beat Syros Pharmaceuticals' return on equity.

PaxMedica has a beta of -0.99, suggesting that its stock price is 199% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 1.61, suggesting that its stock price is 61% more volatile than the S&P 500.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

4.9% of PaxMedica shares are held by institutional investors. Comparatively, 0.6% of Genocea Biosciences shares are held by institutional investors. 1.0% of PaxMedica shares are held by company insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Genocea Biosciences' return on equity of -182.88% beat PaxMedica's return on equity.

PaxMedica has higher earnings, but lower revenue than Genocea Biosciences. PaxMedica is trading at a lower price-to-earnings ratio than Genocea Biosciences, indicating that it is currently the more affordable of the two stocks.

PaxMedica has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500. Comparatively, Genocea Biosciences has a beta of 2.53, suggesting that its share price is 153% more volatile than the S&P 500.

In the previous week, PaxMedica's average media sentiment score of 0.00 equaled Genocea Biosciences'average media sentiment score.

4.9% of PaxMedica shares are held by institutional investors. 1.0% of PaxMedica shares are held by insiders. Comparatively, 1.6% of Genocea Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Genocea Biosciences' return on equity of 0.00% beat PaxMedica's return on equity.

Comera Life Sciences has higher revenue and earnings than PaxMedica. PaxMedica is trading at a lower price-to-earnings ratio than Comera Life Sciences, indicating that it is currently the more affordable of the two stocks.

In the previous week, Comera Life Sciences' average media sentiment score of 0.00 equaled PaxMedica'saverage media sentiment score.

4.9% of PaxMedica shares are owned by institutional investors. 8.9% of Comera Life Sciences shares are owned by insiders. Comparatively, 1.0% of PaxMedica shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Comera Life Sciences has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, PaxMedica has a beta of -0.99, suggesting that its share price is 199% less volatile than the S&P 500.

Comera Life Sciences' return on equity of 0.00% beat PaxMedica's return on equity.